GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » Intrinsic Value: Projected FCF

ClouDr Group (HKSE:09955) Intrinsic Value: Projected FCF : HK$0.00 (As of May. 31, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-31), ClouDr Group's Intrinsic Value: Projected FCF is HK$0.00. The stock price of ClouDr Group is HK$2.67. Therefore, ClouDr Group's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for ClouDr Group's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:09955's Price-to-Projected-FCF is not ranked *
in the Medical Distribution industry.
Industry Median: 0.96
* Ranked among companies with meaningful Price-to-Projected-FCF only.

ClouDr Group Intrinsic Value: Projected FCF Historical Data

The historical data trend for ClouDr Group's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group Intrinsic Value: Projected FCF Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of ClouDr Group's Intrinsic Value: Projected FCF

For the Medical Distribution subindustry, ClouDr Group's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClouDr Group's Price-to-Projected-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where ClouDr Group's Price-to-Projected-FCF falls into.



ClouDr Group Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



ClouDr Group  (HKSE:09955) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

ClouDr Group's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.67/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClouDr Group Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of ClouDr Group's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ClouDr Group (HKSE:09955) Business Description

Traded in Other Exchanges
Address
No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Executives
Trident Trust Company (hk) Limited 2301 Trustee
Data Vantage Development Limited 2201 Interest of corporation controlled by you
Kuang Ming 2201 Interest of corporation controlled by you
Prime Forest Assets Limited 2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing 2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan 2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd. 2201 Interest of corporation controlled by you
Haoyuan Health Limited 2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines